Health Dictionary Find a Doctor

Steatorrhea

Template:DiseaseDisorder infobox

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vindhya BellamKonda, M.B.B.S [2] Aditya Ganti M.B.B.S. [3]

Overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Vindhya BellamKonda, M.B.B.S [2]

Overview

Steatorrhea is the formation of non-solid feces. Stools may also float due to excess fat from malabsorption, have an oily appearance and be foul smelling. An oily anal leakage or some level of fecal incontinence may occur. There is increased fat excretion, which can be measured by determining the fecal fat level. While definitions have not been standardized, fat excretion in feces in excess of 0.3 (g/kg) / day is considered indicative of steatorrhea. Based on underlying etiology steatorrhea can be classified into 3 types, intestinal, biliary, and pancreatic steatorrhea. Steatorrhea occurs as a result of either defect of the normal architecture of digestive tract or defect of synthesis or secretion of enzymes required for metabolism fats. Steatorrhea may be caused by Celiac diseasecholedocholithiasiscystic fibrosisexocrine pancreatic insufficiencyhypolipidemic drugsinflammatory bowel diseasesmall bowel bacterial overgrowth syndrome. Common risk factors in the development of steatorrhea include Celiac diseasecystic fibrosisexocrine pancreatic insufficiencyinflammatory bowel diseasesmall intestinal bacterial overgrowthhypolipidemic drugs. If left untreated, steatorrhea can lead to severe malnutrition due to inability of gastrointestinal tract to absorb fat soluble vitamins and ultimately severe weight loss. Complication of steatorrhea include anemiaintestinal obstructionweight loss. Prognosis of steatorrhea is generally good with appropriate treatment. The 72 hr-fecal fat determination is the gold standard test for the diagnosis of steatorrhea. Mild steatorrhea can manifest as passage of frothy, foul smelling stool, greasy in appearance and difficult to flush, abdominal pain, bloating, heart burn. if severe it may cause malnutrition , dehydration, anemia, muscle weakness, weight loss, skin problems, neurological problems, osteoporosis. Patients with steatorrhea usually appear emaciated secondary to loss of subcutaneous fat. Physical examination of patients with steatorrhea is usually remarkable for distended abdomen, orthostatic hypo-tension and ecchymosesChvostek sign and Trousseau sign secondary to hypocalcemia. There are no specific laboratory findings associated with steatorrhea. Management of steatorrhea include treatment of underlying etiology, control of diarrhea and correction of nutritional deficiencies. Surgery is usually reserved for patients with refractory or pre-malignant complications, such as Enteropathy Associated T-cell Lymphoma (EATL) and ulcerative jejunitis (UJ). Effective measures for the primary prevention of steatorrhea include smoking cessation, alcohol cessation, minimizing the use of certain medications, such as antibiotics, that can alter normal bowel flora, and consuming diet rich in dietary fiber.

Historical Perspective

The history of celiac disease dates back to late 1800’s when an english scientist described celiac disease. In October 1887, Samuel Gee, a pediatrician, was the first to describe in detail celiac disease and its association with fatty stools. In 1950, Wim Dicke’s colleagues, Weijers and Van de Kamer, presented a way to diagnose mal-absorption syndromes by using stool fat measurement. In late 1960’s case of idiopathic steatoeehea and reticulosis of the small bowel as a late complication was reported.

Classification

Steatorrhea may be classified based on etiology into 3 types, intestinal, biliary, and pancreatic steatorrhea.

Pathophysiology

Stearorhea can be defined as loss of undigested fat in stools. The processes can be invoked by either defect of the normal architecture of digestive tract or it may involve defect of synthesis or secretion of enzymes of GI tract which are needed to metabolize fatty content of food.

Causes

Steatorrhea may be caused by Celiac disease, choledocholithiasis, cystic fibrosis, exocrine pancreatic insufficiency, hypolipidemic drugs, inflammatory bowel disease, small bowel bacterial overgrowth syndrome.

Differentiating steatorrhea from other Diseases

Steatorrhea must be differentiated from other causes of mal-absorption such as cystic fibrosis, Hartnup’sdisease, Whipple’s disease, Zollinger Ellison syndrome, acrodermatitis enteropathica, intestinal lymphangiectasia.

Epidemiology and Demographics

The demographic measures of steatorrhea can be explained by independent causes of steatorrhea.

Risk Factors

Common risk factors in the development of steatorrhea include: Celiac disease, cystic fibrosis, exocrine pancreatic insufficiency, inflammatory bowel disease, small intestinal bacterial overgrowth, hypolipidemic drugs

Screening

There is insufficient evidence to recommend routine screening for steatorrhea

Natural History, Complications, and Prognosis

If left untreated, steatorrhea can lead to severe malnutrition due to inability of gastrointestinal tract to absorb fat soluble vitamins and ultimately severe weight loss. Complication of steatorrhea include anemia, intestinal obstruction, weight loss. Prognosis of steatorrhea is generally good with appropriate treatment.

Diagnosis

Diagnostic study of choice

The 72 hr-fecal fat determination is the gold standard test for the diagnosis of steatorrhea

History and Symptoms

Mild steatorrhea can manifest as passage of frothy, foul smelling stool, greasy in appearance and difficult to flush, abdominal pain, bloating, heart burn. if severe it may cause malnutrition , dehydration,anemia, muscle weakness, weight loss, skin problems, neurological problems, osteoporosis.

Physical Examination

Patients with steatorrhea usually appear emaciated secondary to loss of subcutaneous fat. Physical examination of patients with steatorrhea is usually remarkable for distended abdomen, orthostatic hypo-tension and ecchymoses, Chvostek sign and Trousseau sign secondary to hypocalcemia.

Laboratory Findings

Quantitative analysis of fat in the stool may be helpful in the diagnosis of steatorrhea. The various tests that may be helpful in the diagnosis are acid steatocrit, near-infrared reflectance analysis (NIRA) and sudan III stain.

Imaging Findings

X-ray

There are no x-ray findings associated with steatorrhea. However, there are x-ray findings depends on the underlying causes.

CT scan

There are no CT scan findings associated with steatorrhea. However, there are CT scan findings depends on the underlying causes

MRI

There are no MRI findings associated with steatorrhea. However, there are MRI findings depends on the underlying causes.

Other Diagnostic Studies

There are no other diagnostic studies associated with steatorrhea. However, there are no other diagnostic studies depends on the underlying causes.

Treatment

Medical Therapy

Management of steatorrhea include treatment of underlying etiology, control of diarrhea and correction of nutritional deficiencies.

Surgery

Surgical intervention is usually not recommended for the management of steatorrhea. Surgery is usually reserved for patients with refractory or pre-malignant complications, such as Enteropathy Associated T-cell Lymphoma (EATL) and ulcerative jejunitis (UJ). EATL patients presenting with ulcerative lesions, stenotic lesions, and perforation needs surgical intervention. Surgery also serves as a pre-therapy in order to prevent perforation of the small bowel during chemotherapy in case of EATL. After surgery patients receive immunotherapy, chemotherapy and/or stem cell transplantation

Primary Prevention

Effective measures for the primary prevention of steatorrhea include smoking cessation, alcohol cessation, minimizing the use of certain medications, such as antibiotics, that can alter normal bowel flora, and consuming diet rich in dietary fiber.

Secondary Prevention

Secondary preventive measures of steatorrhea are similar to primary preventive measures.

References

Template:WS Template:WH

Historical Perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vindhya BellamKonda, M.B.B.S [2]

Historical Perspective

Steato means relating to fatty matter or tissue and rrhea means discharge; flow. So the word means flow of fatty matter. Malabsorption is a condition which is associated with impaired absorption of one or all dietary nutrients. There are multiple etiologies with diminished intestinal absorption. Many of them present with diarrhea, especially steatorrhea. Some of the main causes of steatorrhea are celiac disease, cystic fibrosis, pancreatic insufficiency, small intestinal bacterial overgrowth syndrome. The history of celiac disease dates back to late 1800’s when an english scientist described celiac disease.

Historical perspective and Land marks

  • In October 1887, Samuel Gee, an English leading authority in pediatrics, gained the full credit of explanation of celiac disease, presenting a lecture named “celiac affection” to medical students; which was published next year.
  • In 1950, Wim Dicke, a Dutch pediatrician, suggested in his doctoral thesis that elimination of wheat, rye, and oats from diet would result in reasonable cure of celiac disease. He also described the pathological factor gluten in pathophysiology of Celiac disease.[1]d
  • At the same time, Wim Dicke’s colleagues, Weijers and Van de Kamer, presented a way to diagnose celiac disease by using stool fat measurement.[2]
  • In late 1960’s case of idiopathic steatoeehea and reticulosis of the small bowel as a late complication was reported.[3]
  • Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency ia an important land mark in the 21st century.[4]
  • The CFTR gene was discovered first in 1989.
  • In 1990, scientists successfully added cloned normal gene to Cystic Fibrosis cells in the laboratory, which corrected the chloride transportation.

References

  1. Dicke, W. K.; Weijers, H. A.; KAMER, J. H. v. D. (1953). “Coeliac Disease The Presence in Wheat of a Factor Having a Deleterious Effect in Cases of Coeliac Disease”. Acta Paediatrica. 42 (1): 34–42. doi:10.1111/j.1651-2227.1953.tb05563.x. ISSN 0803-5253.
  2. Kamer, J. H. Van De; Weijers, H. A.; Dicke, W. K. (1953). “Coeliac Disease: An Investigation into the Injurious Constituents of Wheat in Connection with their Action on Patients with Coeliac Disease”. Acta Paediatrica. 42 (3): 223–231. doi:10.1111/j.1651-2227.1953.tb05586.x. ISSN 0803-5253.
  3. PROWSE CB (1950). “Idiopathic steatorrhoea”. Proc. R. Soc. Med. 43 (11): 895–6. PMC 2081764. PMID 14797703.
  4. Trang T, Chan J, Graham DY (2014). “Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency in the 21(st) century”. World J. Gastroenterol. 20 (33): 11467–85. doi:10.3748/wjg.v20.i33.11467. PMC 4155341. PMID 25206255.

Template:WS Template:WH

Classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Vindhya BellamKonda, M.B.B.S [2] Sunny Kumar MD [3]

Overview

Steatorrhea may be classified based on etiology into 3 types, intestinal, biliary, and pancreatic steatorrhea.

Classification

Steatorrhea may be classified based on etiology into 3 types, intestinal, biliary, and pancreatic steatorrhea.[1][2][3][4]

References

  1. Kumar R, Bhargava A, Jaiswal G (2017). “A case report on total pancreatic lipomatosis: An unusual entity”. Int J Health Sci (Qassim). 11 (4): 71–73. PMC 5654180. PMID 29085272.
  2. Previti E, Salinari S, Bertuzzi A, Capristo E, Bornstein S, Mingrone G (2017). “Glycemic control after metabolic surgery: a Granger causality and graph analysis”. Am J Physiol Endocrinol Metab. 313 (5): E622–E630. doi:10.1152/ajpendo.00042.2017. PMID 28698280.
  3. Vakhrushev YM, Lukashevich AP (2017). “[Specific features of impaired intestinal digestion, absorption, and microbiocenosis in patients with cholelithiasis]”. Ter Arkh. 89 (2): 28–32. doi:10.17116/terarkh201789228-32. PMID 28281512.
  4. Scarpignato C, Gatta L, Zullo A, Blandizzi C, SIF-AIGO-FIMMG Group. Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners (2016). “Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression”. BMC Med. 14 (1): 179. doi:10.1186/s12916-016-0718-z. PMC 5101793. PMID 27825371.

Template:WS Template:WH

Pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Sunny Kumar MD [2]

Overview

Steatrorhea can be defined as loss of undigested fat in stools. The processes can be invoked by either defect of the normal architecture of digestive tract or it may involve defect of synthesis or secretion of enzymes of GI tract which are needed to metabolize fatty content of food.

Pathophysiology

Normal Fat absorption

To understand the pathophysiology of fat malabsoption we need to understand normal physiology of fat metabolization:[1][2][3][4][5][6][7][8]

Pathogenesis

Any disturbance in the normal physiology results in decreased absorption of the fats.

Genetics:

The development of steatorrhea is the result of multiple genetic mutations. Common genetic conditions associated with steatorrhea include:

Gross pathology

On gross pathology the gastro-intestinal tract looks normal in conditions which involves enzyme deficiencies. However in condition which involves obstruction of ducts involved in secretion of enzymes will look narrowed. The luminal causes which damage the luman of GIT and does not allow the absoption of faty products will also look ulcerated.

Microscopic pathology

On microscopy the GIT looks normal in conditions which involves enzyme deficiencies. However in condition which involves obstruction of ducts involved in secretion of enzymes will look narrowed. The luminal causes which damage the luman of GIT and does not allow the absoption of faty products will also look ulcerated.

References

  1. Kumar R, Bhargava A, Jaiswal G (2017). “A case report on total pancreatic lipomatosis: An unusual entity”. Int J Health Sci (Qassim). 11 (4): 71–73. PMC 5654180. PMID 29085272.
  2. Previti E, Salinari S, Bertuzzi A, Capristo E, Bornstein S, Mingrone G (2017). “Glycemic control after metabolic surgery: a Granger causality and graph analysis”. Am J Physiol Endocrinol Metab. 313 (5): E622–E630. doi:10.1152/ajpendo.00042.2017. PMID 28698280.
  3. Vakhrushev YM, Lukashevich AP (2017). “[Specific features of impaired intestinal digestion, absorption, and microbiocenosis in patients with cholelithiasis]”. Ter Arkh. 89 (2): 28–32. doi:10.17116/terarkh201789228-32. PMID 28281512.
  4. Scarpignato C, Gatta L, Zullo A, Blandizzi C, SIF-AIGO-FIMMG Group. Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners (2016). “Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression”. BMC Med. 14 (1): 179. doi:10.1186/s12916-016-0718-z. PMC 5101793. PMID 27825371.
  5. Podboy A, Anderson BW, Sweetser S (2016). “61-Year-Old Man With Chronic Diarrhea”. Mayo Clin Proc. 91 (2): e23–8. doi:10.1016/j.mayocp.2015.07.033. PMID 26769182.
  6. Burnett JR, Hooper AJ (2015). “Vitamin E and oxidative stress in abetalipoproteinemia and familial hypobetalipoproteinemia”. Free Radic Biol Med. 88 (Pt A): 59–62. doi:10.1016/j.freeradbiomed.2015.05.044. PMID 26086616.
  7. Valenzise M, Alessi L, Bruno E, Cama V, Costanzo D, Genovese C; et al. (2016). “APECED syndrome in childhood: clinical spectrum is enlarging”. Minerva Pediatr. 68 (3): 226–9. PMID 25502918.
  8. Wilcox C, Turner J, Green J (2014). “Systematic review: the management of chronic diarrhoea due to bile acid malabsorption”. Aliment Pharmacol Ther. 39 (9): 923–39. doi:10.1111/apt.12684. PMID 24602022.

Template:WS Template:WH

Causes

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vindhya BellamKonda, M.B.B.S [2]

Overview

Steatorrhea may be caused by Celiac disease, choledocholithiasis, cystic fibrosis, exocrine pancreatic insufficiency, hypolipidemic drugs, inflammatory bowel disease, small bowel bacterial overgrowth syndrome.

Causes

Common causes

Steatorrhea may be caused by.[1][2][3][4][5]

Less Common causes

Less common causes of steatorrhea include:[6][7][8][9]

Causes by Organ System

Cardiovascular No underlying causes
Chemical/Poisoning No underlying causes
Dental No underlying causes
Dermatologic No underlying causes
Drug Side Effect Hypolipidemic agent,  Lanreotide,  Octreotide.
Ear Nose Throat No underlying causes
Endocrine  Graves’ disease,  Hyperthyroidism,
Environmental No underlying causes
Gastroenterologic Angiodysplasia, Bacterial overgrowth, Celiac disease, Cholecystectomy, Choledocholithiasis, Chronic atrophic gastritis, Chronic pancreatitis, Diverticulosis, Inflammatory bowel disease, Mesenteric ischemia, Post-gastrectomy, Post-vagotomy, Primary bile acid malabsorption  , Primary sclerosing cholangitis, Radiation enteropathy, Short bowel syndrome, Strictures.
Genetic Abetalipoproteinemia, Cystic fibrosis  , Diacylglycerol acyltransferase 1 deficiency, Johanson-blizzard syndrome  , Pancreatic lipase deficiency, Pearson syndrome, Shwachman-Diamond syndrome.
Hematologic No underlying causes
Iatrogenic No underlying causes
Infectious Disease Fish tape worm, Giardiasis  , HIV related malabsorption, Hookworm, Round worm, Tropical sprue, Whipple’s disease
Musculoskeletal/Orthopedic No underlying causes
Neurologic No underlying causes
Nutritional/Metabolic No underlying causes
Obstetric/Gynecologic No underlying causes
Oncologic Colorectal cancer, Pancreatic cancer, Zollinger-Ellison syndrome.
Ophthalmologic No underlying causes
Overdose/Toxicity No underlying causes
Psychiatric No underlying causes
Pulmonary No underlying causes
Renal/Electrolyte No underlying causes
Rheumatology/Immunology/Allergy Systemic sclerosis
Sexual No underlying causes
Trauma No underlying causes
Urologic No underlying causes
Miscellaneous Natural fats (Butterfish, Escolar, Oilfish), Artificial fats (Olestra).

Causes in Alphabetical Order

References

  1. Scarpignato C, Gatta L, Zullo A, Blandizzi C, SIF-AIGO-FIMMG Group. Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners (2016). “Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression”. BMC Med. 14 (1): 179. doi:10.1186/s12916-016-0718-z. PMC 5101793. PMID 27825371.
  2. Podboy A, Anderson BW, Sweetser S (2016). “61-Year-Old Man With Chronic Diarrhea”. Mayo Clin Proc. 91 (2): e23–8. doi:10.1016/j.mayocp.2015.07.033. PMID 26769182.
  3. Burnett JR, Hooper AJ (2015). “Vitamin E and oxidative stress in abetalipoproteinemia and familial hypobetalipoproteinemia”. Free Radic Biol Med. 88 (Pt A): 59–62. doi:10.1016/j.freeradbiomed.2015.05.044. PMID 26086616.
  4. Valenzise M, Alessi L, Bruno E, Cama V, Costanzo D, Genovese C; et al. (2016). “APECED syndrome in childhood: clinical spectrum is enlarging”. Minerva Pediatr. 68 (3): 226–9. PMID 25502918.
  5. Wilcox C, Turner J, Green J (2014). “Systematic review: the management of chronic diarrhoea due to bile acid malabsorption”. Aliment Pharmacol Ther. 39 (9): 923–39. doi:10.1111/apt.12684. PMID 24602022.
  6. “Weighing a Pill For Weight Loss”. Washington Post. Retrieved 2007-07-06. While the Food and Drug Administration (FDA) still must approve the switch, the agency often follows the advice of its experts. If it does, Orlistat (xenical) — currently sold only by prescription — could be available over-the-counter (OTC) later this year. But it’s important to know that the weight loss that’s typical for users of the drug — 5 to 10 percent of total weight — will be less than many dieters expect. And many consumers may be put off by the drug’s significant gastrointestinal side effects, including flatulence, diarrhea and anal leakage.
  7. “Frito-Lay Study: Olestra Causes “Anal Oil Leakage. Center for Science in the Public Interest. Thursday, February 13, 1997. Retrieved 2007-07-07. The Frito-Lay report states: “The anal oil leakage symptoms were observed in this study (3 to 9% incidence range above background), as well as other changes in elimination. … Underwear spotting was statistically significant in one of two low level consumer groups at a 5% incidence above background.” Despite those problems, the authors of the report concluded that olestra-containing snacks “should have a high potential for acceptance in the marketplace.” Check date values in: |date= (help)
  8. “The Word Is ‘Leakage’. Accidents may happen with a new OTC diet drug”. Newsweek. June 25, 2007. Retrieved 2007-06-21. GlaxoSmithKline has a tip for people who decide to try Alli, the over-the-counter weight-loss drug it is launching with a multimillion-dollar advertising blitz—keep an extra pair of pants handy. That’s because Alli, a lower-dose version of the prescription drug Xenical, could (cue the late-night talk-show hosts) make you soil your pants. But while Alli’s most troublesome side effect, anal leakage, is sure to be good for a few laughs, millions of people who are desperate to take off weight may still decide the threat of an accident is worth it.
  9. “Reported medical side-effects of Olestra according to Procter and Gamble studies”. Center for Science in the Public Interest. Retrieved 2007-06-21. Olestra sometimes causes underwear staining associated with “anal leakage.” Olestra sometimes causes underwear staining. That phenomenon may be caused most commonly by greasy, hard-to-wipe-off fecal matter, but occasionally also from anal leakage (leakage of liquid olestra through the anal sphincter).

Template:WS Template:WH

Differentiating Steatorrhea from other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vindhya BellamKonda, M.B.B.S [2] Aravind Reddy Kothagadi M.B.B.S[3]

Overview

Steatorrhea must be differentiated from other causes of mal-absorption such as cystic fibrosis, Hartnup’sdisease, Whipple’s disease, Zollinger Ellison syndrome, acrodermatitis enteropathica, intestinal lymphangiectasia.

Steatorrhea differential diagnosis

The following table outlines the major differential diagnoses of malabsorption.[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30]

Categories Cause Clinical manifestation Lab findings
Symptoms Findings
Duration Diarrhea Fever Abdominal pain Weight loss
Stool exam CBC
Acute Chronic Watery Bloody Fatty WBC Hgb Plt
Gastrointestinal Crohn’s disease + + + + ± + + WBC +

RBC +

Ulcerative colitis + + + + ± + + WBC +

RBC +

Celiac disease + ± ± + + Fat droplets on sudan stain Nl Nl
Cause Duration Diarrhea Fever Abdominal pain Weight loss Findings Stool exam CBC
Acute Chronic Watery Bloody Fatty WBC Hgb Plt
Cystic fibrosis + + ± + + Fat droplets on sudan stain Nl Nl
Chronic pancreatitis + + + + + Fat droplets on sudan stain

Fecal elastase +

Nl Nl Nl
Bile acid malabsorption + + + + Fat droplets on sudan stain Nl Nl Nl
Lactose intolerance + + + + Nl Nl Nl
Infection Bacterial Cause Duration Diarrhea Fever Abdominal pain Weight loss Findings Stool exam CBC
Acute Chronic Watery Bloody Fatty WBC Hgb Plt
Whipple’s disease + + + ± + + Fecal fat + ↓/↑
Tropical sprue + + + + + + + WBC +

Stool culture +

Nl Nl
Small bowel bacterial overgrowth + + + + + WBC +

Stool culture +

Fecal fat +

Nl Nl
Cause Duration Diarrhea Fever Abdominal pain Weight loss Findings Stool exam CBC
Acute Chronic Watery Bloody Fatty WBC Hgb Plt
Virus HIV + + + + + WBC + Nl
Parasite Giardia + + + + + Ova + Nl Nl Nl
Isospora + + + + + + + WBC +

RBC +

Ova +

Fecal fat +

Nl Nl
Tumors VIPoma + + + + + + Nl Nl Nl
Zollinger–Ellison syndrome + + + + + + Nl Nl
Cause Duration Diarrhea Fever Abdominal pain Weight loss Findings Stool exam CBC
Acute Chronic Watery Bloody Fatty WBC Hgb Plt
Lymphoma + + + + + + RBC + Nl Nl
Medication/Toxicity + + + ± ± + + Nl Nl
Iatrogenic Short bowel syndrome + + + + + Fecal fat + Nl
Radiation enteritis + + + + + + + WBC +

RBC +

Fecal fat +

Nl Nl
Others Cause Duration Diarrhea Fever Abdominal pain Weight loss Findings Stool exam CBC
Acute Chronic Watery Bloody Fatty WBC Hgb Plt
Abetalipoproteinemia + + + + + Nl Nl Nl
Hyperthyroidism + + ± + +
  • Lump in the neck
Fecal fat + Nl Nl Nl
Diabetic neuropathy + + + + + Fecal fat + Nl Nl
Systemic sclerosis + + ± + + + RBC +

Fecal fat +

Nl Nl

References

  1. Casburn-Jones, Anna C; Farthing, Michael Jg (2004). “Traveler’s diarrhea”. Journal of Gastroenterology and Hepatology. 19 (6): 610–618. doi:10.1111/j.1440-1746.2003.03287.x. ISSN 0815-9319.
  2. Kamat, Deepak; Mathur, Ambika (2006). “Prevention and Management of Travelers’ Diarrhea”. Disease-a-Month. 52 (7): 289–302. doi:10.1016/j.disamonth.2006.08.003. ISSN 0011-5029.
  3. Pfeiffer, Margaret L.; DuPont, Herbert L.; Ochoa, Theresa J. (2012). “The patient presenting with acute dysentery – A systematic review”. Journal of Infection. 64 (4): 374–386. doi:10.1016/j.jinf.2012.01.006. ISSN 0163-4453.
  4. Barr W, Smith A (2014). “Acute diarrhea”. Am Fam Physician. 89 (3): 180–9. PMID 24506120.
  5. Amil Dias J (2017). “Celiac Disease: What Do We Know in 2017?”. GE Port J Gastroenterol. 24 (6): 275–278. doi:10.1159/000479881. PMID 29255768.
  6. Kotloff KL, Riddle MS, Platts-Mills JA, Pavlinac P, Zaidi A (2017). “Shigellosis”. Lancet. doi:10.1016/S0140-6736(17)33296-8. PMID 29254859. Vancouver style error: initials (help)
  7. Yamamoto-Furusho, J.K.; Bosques-Padilla, F.; de-Paula, J.; Galiano, M.T.; Ibañez, P.; Juliao, F.; Kotze, P.G.; Rocha, J.L.; Steinwurz, F.; Veitia, G.; Zaltman, C. (2017). “Diagnóstico y tratamiento de la enfermedad inflamatoria intestinal: Primer Consenso Latinoamericano de la Pan American Crohn’s and Colitis Organisation”. Revista de Gastroenterología de México. 82 (1): 46–84. doi:10.1016/j.rgmx.2016.07.003. ISSN 0375-0906.
  8. Borbély, Yves M; Osterwalder, Alice; Kröll, Dino; Nett, Philipp C; Inglin, Roman A (2017). “Diarrhea after bariatric procedures: Diagnosis and therapy”. World Journal of Gastroenterology. 23 (26): 4689. doi:10.3748/wjg.v23.i26.4689. ISSN 1007-9327.
  9. Crawford, Sue E.; Ramani, Sasirekha; Tate, Jacqueline E.; Parashar, Umesh D.; Svensson, Lennart; Hagbom, Marie; Franco, Manuel A.; Greenberg, Harry B.; O’Ryan, Miguel; Kang, Gagandeep; Desselberger, Ulrich; Estes, Mary K. (2017). “Rotavirus infection”. Nature Reviews Disease Primers. 3: 17083. doi:10.1038/nrdp.2017.83. ISSN 2056-676X.
  10. Kist M (2000). “[Chronic diarrhea: value of microbiology in diagnosis]”. Praxis (Bern 1994) (in German). 89 (39): 1559–65. PMID 11068510.
  11. Guerrant RL, Shields DS, Thorson SM, Schorling JB, Gröschel DH (1985). “Evaluation and diagnosis of acute infectious diarrhea”. Am. J. Med. 78 (6B): 91–8. PMID 4014291.
  12. López-Vélez R, Turrientes MC, Garrón C, Montilla P, Navajas R, Fenoy S, del Aguila C (1999). “Microsporidiosis in travelers with diarrhea from the tropics”. J Travel Med. 6 (4): 223–7. PMID 10575169.
  13. Wahnschaffe, Ulrich; Ignatius, Ralf; Loddenkemper, Christoph; Liesenfeld, Oliver; Muehlen, Marion; Jelinek, Thomas; Burchard, Gerd Dieter; Weinke, Thomas; Harms, Gundel; Stein, Harald; Zeitz, Martin; Ullrich, Reiner; Schneider, Thomas (2009). “Diagnostic value of endoscopy for the diagnosis of giardiasis and other intestinal diseases in patients with persistent diarrhea from tropical or subtropical areas”. Scandinavian Journal of Gastroenterology. 42 (3): 391–396. doi:10.1080/00365520600881193. ISSN 0036-5521.
  14. Mena Bares LM, Carmona Asenjo E, García Sánchez MV, Moreno Ortega E, Maza Muret FR, Guiote Moreno MV, Santos Bueno AM, Iglesias Flores E, Benítez Cantero JM, Vallejo Casas JA (2017). “75SeHCAT scan in bile acid malabsorption in chronic diarrhoea”. Rev Esp Med Nucl Imagen Mol. 36 (1): 37–47. doi:10.1016/j.remn.2016.08.005. PMID 27765536.
  15. Gibson RJ, Stringer AM (2009). “Chemotherapy-induced diarrhoea”. Curr Opin Support Palliat Care. 3 (1): 31–5. doi:10.1097/SPC.0b013e32832531bb. PMID 19365159.
  16. Abraham BP, Sellin JH (2012). “Drug-induced, factitious, & idiopathic diarrhoea”. Best Pract Res Clin Gastroenterol. 26 (5): 633–48. doi:10.1016/j.bpg.2012.11.007. PMID 23384808.
  17. Reintam Blaser A, Deane AM, Fruhwald S (2015). “Diarrhoea in the critically ill”. Curr Opin Crit Care. 21 (2): 142–53. doi:10.1097/MCC.0000000000000188. PMID 25692805.
  18. McMahan ZH, DuPont HL (2007). “Review article: the history of acute infectious diarrhoea management–from poorly focused empiricism to fluid therapy and modern pharmacotherapy”. Aliment. Pharmacol. Ther. 25 (7): 759–69. doi:10.1111/j.1365-2036.2007.03261.x. PMID 17373914.
  19. Schiller LR (2012). “Definitions, pathophysiology, and evaluation of chronic diarrhoea”. Best Pract Res Clin Gastroenterol. 26 (5): 551–62. doi:10.1016/j.bpg.2012.11.011. PMID 23384801.
  20. Giannella RA (1986). “Chronic diarrhea in travelers: diagnostic and therapeutic considerations”. Rev. Infect. Dis. 8 Suppl 2: S223–6. PMID 3523719.
  21. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR; et al. (2005). “Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology”. Can J Gastroenterol. 19 Suppl A: 5A–36A. PMID 16151544.
  22. Sauter GH, Moussavian AC, Meyer G, Steitz HO, Parhofer KG, Jüngst D (2002). “Bowel habits and bile acid malabsorption in the months after cholecystectomy”. Am J Gastroenterol. 97 (7): 1732–5. doi:10.1111/j.1572-0241.2002.05779.x. PMID 12135027.
  23. Maiuri L, Raia V, Potter J, Swallow D, Ho MW, Fiocca R; et al. (1991). “Mosaic pattern of lactase expression by villous enterocytes in human adult-type hypolactasia”. Gastroenterology. 100 (2): 359–69. PMID 1702075.
  24. RUBIN CE, BRANDBORG LL, PHELPS PC, TAYLOR HC (1960). “Studies of celiac disease. I. The apparent identical and specific nature of the duodenal and proximal jejunal lesion in celiac disease and idiopathic sprue”. Gastroenterology. 38: 28–49. PMID 14439871.
  25. Konvolinka CW (1994). “Acute diverticulitis under age forty”. Am J Surg. 167 (6): 562–5. PMID 8209928.
  26. Satsangi J, Silverberg MS, Vermeire S, Colombel JF (2006). “The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications”. Gut. 55 (6): 749–53. doi:10.1136/gut.2005.082909. PMC 1856208. PMID 16698746.
  27. Haque R, Huston CD, Hughes M, Houpt E, Petri WA (2003). “Amebiasis”. N Engl J Med. 348 (16): 1565–73. doi:10.1056/NEJMra022710. PMID 12700377.
  28. Hertzler SR, Savaiano DA (1996). “Colonic adaptation to daily lactose feeding in lactose maldigesters reduces lactose intolerance”. Am J Clin Nutr. 64 (2): 232–6. PMID 8694025.
  29. Briet F, Pochart P, Marteau P, Flourie B, Arrigoni E, Rambaud JC (1997). “Improved clinical tolerance to chronic lactose ingestion in subjects with lactose intolerance: a placebo effect?”. Gut. 41 (5): 632–5. PMC 1891556. PMID 9414969.
  30. BLACK-SCHAFFER B (1949). “The tinctoral demonstration of a glycoprotein in Whipple’s disease”. Proc Soc Exp Biol Med. 72 (1): 225–7. PMID 15391722.

Template:WS Template:WH

Epidemiology and Demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sunny Kumar MD [2]

Overview

The demographic measures of steatorrhea can be explained by independent causes of steatorrhea.

Epidemiology and Demographics

Following are common causes and their independent demographic variables.

Celiac disease:

Incidence:

  • The incidence of celiac disease is approximately 10-13 per 100,000 individuals worldwide.
  • In United States the incidence of celiac disease is approximately 10 per 100,000 individuals.
  • The incidence of celiac disease has been increasing over the years. This can be attributed to increasing use of serologic screening, leading to more accurate results and early diagnosis in cases of mild disease. A general trend in incidence of celiac disease over the years is as under:
    • In 1950, the incidence of celiac disease was estimated to be 1 case per 100,000 individuals worldwide.
    • In 1960-1980, the incidence of celiac disease was estimated to be 2 cases per 100,000 individuals worldwide.
    • In 1990, the incidence of celiac disease was estimated to be 3-5 cases per 100,000 individuals worldwide.
    • In 2000, the incidence of celiac disease was estimated to be 9 cases per 100,000 individuals worldwide.

Prevalence:

  • Worldwide, the prevalence of celiac disease is estimated to be 500 to 1000 per 100,000 individuals.
  • In United States, the prevalence of celiac disease is approximately 710 per 100,000 individuals.
  • The overall prevalence of celiac disease has been increasing in United States from 170 per 100,000 individuals in 1988 to 440 per 100,000 individuals in 2012.
  • In Europe the prevalence of celiac disease is estimated to be 1000 per 100,000 individuals. The Scandinavian countries, Ireland, and the United Kingdom population tended to show a higher prevalenceof celiac disease of approximately 1000 to 1500 per 100,000 individuals.
  • In Australia the prevalence of celiac disease is estimated to be 400 per 100,000 individuals.
  • In New Zealand the prevalence of celiac disease is estimated to be 1200 per 100,000 individuals.
  • In India the prevalence of celiac disease is estimated to be 300 per 100,000 individuals.
  • In North Africa, Algeria with its refugees in the Sahara desert have the highest prevalence of celiac disease at 5600 per 100,000 individuals.
  • The risk for celiac disease is higher for people with diabetes, autoimmune disorder and relatives with celiac disease individuals because of shared HLA typing.

Age:

  • Celiac disease affects children and adults alike.
  • In children celiac disease peaks in early childhood.
  • In adults celiac disease is usually diagnosed around fourth and fifth decades of life.

Race:

  • Celiac disease usually affects individuals of the non-Hispanic white race (1000 per 100,000 individuals), Hispanics (300 per 100,000 individuals) and non-Hispanic blacks (200 per 100,000 individuals).
  • HLA-DQ2 associated celiac disease is frequently found in white populations located in Western Europe.

Gender:

  • Women are more commonly affected by celiac disease than men.
  • The female to male ratio is approximately 3:1.
  • In contrast, patients over the age of 60 who are diagnosed with celiac disease are most commonly males.

Region:

  • Tthe highest prevalence of celiac disease has been reported in Algerian refugees. These individuals have a high rate of consanguinity and high frequencies of HLA-DQ2.

Cystic fibrosis

Cystic fibrosis (CF) is an autosomal recessive disorder whose incidence has long been estimated as 1/2500 live births in Caucasians.

Small intestinal bacterial overgrowth syndrome

Epidemiology and demographics of small intestinal bacterial overgrowth is as follows: 

Age

  • Small intestinal bacterial overgrowth is more commonly observed among elderly patients.

Gender

  • Small intestinal bacterial overgrowth (SIBO) affects men and women equally.

Race

  • There is no racial predilection for small intestinal bacterial overgrowth (SIBO).

References

Template:WS Template:WH

Risk Factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vindhya BellamKonda, M.B.B.S [2]

Overview

Common risk factors in the development of steatorrhea include Celiac disease, cystic fibrosis, exocrine pancreatic insufficiency, inflammatory bowel disease, small intestinal bacterial overgrowth, hypolipidemic drugs

Risk Factors

References

  1. Pillarisetti N, Williamson E, Linnane B, Skoric B, Robertson CF, Robinson P, Massie J, Hall GL, Sly P, Stick S, Ranganathan S (2011). “Infection, inflammation, and lung function decline in infants with cystic fibrosis”. Am. J. Respir. Crit. Care Med. 184 (1): 75–81. doi:10.1164/rccm.201011-1892OC. PMID 21493738.

Template:WS Template:WH

Screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vindhya BellamKonda, M.B.B.S [2]


Overview

There is insufficient evidence to recommend routine screening for steatorrhea

Screening

There is insufficient evidence to recommend routine screening for steatorrhea

References

Template:WS Template:WH

Natural History, Complications and Prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vindhya BellamKonda, M.B.B.S [2]Sunny Kumar MD [3]

Overview

If left untreated, steatorrhea can lead to severe malnutrition due to inability of gastrointestinal tract to absorb fat soluble vitamins and ultimately severe weight loss. Complication of steatorrhea include anemia, intestinal obstruction, weight loss. Prognosis of steatorrhea is generally good with appropriate treatment.

Natural History

If left untreated, steatorrhea can lead to severe malnutrition due to inability of gastrointestinal tract to absorb fat soluble vitamins and ultimately severe weight loss.atorrhea:[1][2][3]

Complications

Complication of steatorrhea include:[4][5]

Prognosis

Prognosis of steatorrhea is generally good with appropriate treatment.

References

  1. Scarpignato C, Gatta L, Zullo A, Blandizzi C, SIF-AIGO-FIMMG Group. Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners (2016). “Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression”. BMC Med. 14 (1): 179. doi:10.1186/s12916-016-0718-z. PMC 5101793. PMID 27825371.
  2. Podboy A, Anderson BW, Sweetser S (2016). “61-Year-Old Man With Chronic Diarrhea”. Mayo Clin Proc. 91 (2): e23–8. doi:10.1016/j.mayocp.2015.07.033. PMID 26769182.
  3. Burnett JR, Hooper AJ (2015). “Vitamin E and oxidative stress in abetalipoproteinemia and familial hypobetalipoproteinemia”. Free Radic Biol Med. 88 (Pt A): 59–62. doi:10.1016/j.freeradbiomed.2015.05.044. PMID 26086616.
  4. Valenzise M, Alessi L, Bruno E, Cama V, Costanzo D, Genovese C; et al. (2016). “APECED syndrome in childhood: clinical spectrum is enlarging”. Minerva Pediatr. 68 (3): 226–9. PMID 25502918.
  5. Wilcox C, Turner J, Green J (2014). “Systematic review: the management of chronic diarrhoea due to bile acid malabsorption”. Aliment Pharmacol Ther. 39 (9): 923–39. doi:10.1111/apt.12684. PMID 24602022.

Template:WS Template:WH

Diagnosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | X Ray | CT | MRI | Ultrasound | Other Imaging Findings | Other Diagnostic Studies

Treatment

Treatment

Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case Studies

Case #1



Template:WikiDoc Sources

Looking for the patient version?

Back to the patient-friendly article

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH